SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LXRX reported three months ended September 30, 2026 results. The stock moved +8.8% on the print.
LXRXearnings

Earnings reactions, page 6

Lexicon Pharmaceuticals, Inc. (LXRX) FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenues were $11.3 million for the third quarter of 2026.
  • Research and development expenses were $16.2 million for the third quarter of 2026.
  • Selling, general and administrative expenses were $9.5 million for the third quarter of 2026.
  • Net loss for the third quarter of 2026 was $14.0 million, or $0.03 per share.
  • Lexicon had $183.2 million in cash and investments as of September 30, 2026.

Guidance

  • Lexicon continues to expect topline results for SONATA-HCM in the first quarter of 2027.
  • NDA resubmission for ZYNQUISTA is anticipated in the first quarter of 2027.

Price and volatility reaction

The stock moved +8.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -7.8 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release1.482026-11-04
Close after release1.612026-11-05
Realised move+8.8%close to close
30d ATM IV change-7.8 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →